Please login to the form below
Astellas Pharma
This page shows the latest Astellas Pharma news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Astellas’ Xospata for NHS use
However, following further discussions with Astellas, NICE has recommended Xospata monotherapy for treating adult patients with relapsed or refractory FLT3-positive AML. ... no longer works or they relapse,” said Jackie Williams, general manager for
Latest news
-
FDA approves Allergan’s biodegradable glaucoma implant drug
One company looking to develop novel treatments for the ocular disorder is UK gene therapy company Quethera – which was acquired in 2018 by Japan’s Astellas Pharma. ... It would address a high unmet medical need in glaucoma patients who are at risk
-
Astellas files new application for expanded use of roxadustat in Japan
Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... Together with partner FibroGen, Astellas has submitted a supplemental
-
Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal
Closely follows $3bn acquistion of gene therapy specialist Audentes. Japanese pharma company Astellas has inked a deal to buy out US-based biotech Xyphos, to bolster its immuno-oncology pipeline. . ... This deal closely follows Astellas’ $3bn
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... Meanwhile, Seattle and Astellas are also planning to expand
-
Astellas makes gene therapy a core focus with $3bn Audentes buy
Deal includes a late-stage candidate for a rare disease. Astellas has made a foray into gene therapy with the acquisition of Audentes Therapeutics for $3bn, adding a late-stage candidate ... Last year, Astellas dipped its toe into the sector by licensing
FDA approves Allergan’s biodegradable glaucoma implant drug
Astellas files new application for expanded use of roxadustat in Japan
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
More from news
Approximately 1 fully matching, plus 132 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth. ... The data this article was based on is available in full online:
-
Case study: Action on Fistula
Client:Astellas Pharma EMEA Limited. Agency:Forster Communications. Campaign:Action on Fistula. Timescale:. Action on Fistula, launched in May 2014, is an innovative partnership between Astellas Pharma EMEA Limited and the ... Astellas’ investment in
-
Japanese pharma pulls no punches with post-Brexit UK
Yasuo Sakae, vice president of corporate strategy and planning at Astellas Pharma Europe, told PME that the company’s regulatory team for the Europe, Middle East and Africa (EMEA) region is ... globally, as well as the presence of world-class
-
Deal Watch July 2016
$225m. $36m. LEO Pharma. AstraZeneca. $1, 115m. $115m. Astellas. Cytokinetics. $100m. ... In at numbers 2, 3 and 4 are the LEO-AstraZeneca deal with an upfront of $115m, Astellas-Cytokinetics at $95m and Almirall-Sun Pharma at $50m (see below).
-
Astellas: Ten years young
s first decade of operations and hear from two of its senior executives on where Astellas is heading. ... In Europe sales rose 18.5% in 2014 and the region has been of increasing importance to Astellas.
The good, the bad and the ugly
Case study: Action on Fistula
Japanese pharma pulls no punches with post-Brexit UK
Deal Watch July 2016
Astellas: Ten years young
More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
Taylor joins the agency from Astellas, where she was senior director of corporate communications, EMEA. ... run those very departments in global pharma companies and we therefore completely understand the challenges they face.
-
Astellas strengthens US and Canadian leadership team
Astellas has promoted Steve Sabus (pictured right) to general manager of Astellas Pharma Canada, effective from 1 April this year. ... needs.”. Sabus joined Astellas in 2007 and has over 25 years’ experience in the pharmaceutical industry.
-
Astellas promotes Anthony Fiordaliso to VP, Americas finance
He first joined the pharma firm in 2010 from Schering-Plough. Astellas has promoted Anthony Fiodaliso to VP, Americas finance to oversee areas such as managerial reporting and budgeting, financial planning ... In his new role Fiordaliso will report
-
Dendreon appoints new R&D lead
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
-
Astellas appoints new senior VP
Astellas.”. “I’m confident she will make an immediate and positive impact on both the team in the Americas, as well as the patients and partners we serve.”. ... She has also received multiple awards for leadership and innovation through her career
Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
Astellas strengthens US and Canadian leadership team
Astellas promotes Anthony Fiordaliso to VP, Americas finance
Dendreon appoints new R&D lead
Astellas appoints new senior VP
More from appointments
Approximately 0 fully matching, plus 29 partially matching documents found.
Latest from PMHub
-
Dovetail partners with Tillotts AG to map management of C. difficile infection in Europe
Specialist stakeholder engagement consultancy Dovetail, based in London, UK, have announced a new partnership with Tillotts Pharma AG to support the launch of Tillotts’ recent acquisition DIFICLIR in the EU. ... Tillotts Pharma AG recently acquired the
-
emotive boosts health economics and outcomes research team
Since joining emotive in May 2014, he has played a key role in the delivery of a range of creative health economics solutions for a variety of pharma clients, across different ... major pharma clients, including Bayer and Astellas.
-
How to integrate data to drive sales
Inspired by a recent Agnitio roundtable discussion with Allergan, Ariad Pharmaceuticals, Astellas and Ipsen Pharma. As the number of our digital channels and tools continually expand, there are many opportunities to
-
World’s Largest Pharmaceutical Summit Brings Latest Innovations To Light In New Award Ceremony
Astellas Pharma, Bayer, Pfizer and MSD are amongst the shortlisted companies who will join an exclusive celebration to recognise what really matters when it comes to supporting real patient outcomes. ... Customer Innovator Award and Lifetime Value
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
No results were found
PMHub
integrated medhealth communication
imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
